110 related articles for article (PubMed ID: 26299484)
1. Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis.
Taoka Y; Matsumoto K; Ohashi K; Minamida S; Hagiwara M; Nagi S; Saito T; Kodera Y; Iwamura M
Biomed Res; 2015; 36(4):253-61. PubMed ID: 26299484
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
3. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
4. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.
Shiota M; Tsunoda T; Song Y; Yokomizo A; Tada Y; Oda Y; Naito S
BJU Int; 2011 Apr; 107(7):1148-53. PubMed ID: 20726978
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells.
Yoon SJ; Park I; Kwak C; Lee E
Oncol Rep; 2003; 10(5):1363-7. PubMed ID: 12883708
[TBL] [Abstract][Full Text] [Related]
7. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Jiang X; Lei T; Zhang M
Technol Cancer Res Treat; 2018 Jan; 17():1533034618769413. PubMed ID: 29665744
[TBL] [Abstract][Full Text] [Related]
8. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
9. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H
Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258
[TBL] [Abstract][Full Text] [Related]
10. [Screening proteins related to retinoic acid resistance by proteomic analysis].
Qin H; Liu T; Yang JL; Huang X; Liu B; Song X; Zhao X; Wei YQ
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):520-5. PubMed ID: 17459200
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
[TBL] [Abstract][Full Text] [Related]
12. Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis.
Miura N; Takemori N; Kikugawa T; Tanji N; Higashiyama S; Yokoyama M
Mol Oncol; 2012 Jun; 6(3):311-22. PubMed ID: 22265592
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.
Makridakis M; Gagos S; Petrolekas A; Roubelakis MG; Bitsika V; Stravodimos K; Pavlakis K; Anagnou NP; Coleman J; Vlahou A
Proteomics; 2009 Jan; 9(2):287-98. PubMed ID: 19105184
[TBL] [Abstract][Full Text] [Related]
14. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation.
D'Aguanno S; D'Alessandro A; Pieroni L; Roveri A; Zaccarin M; Marzano V; De Canio M; Bernardini S; Federici G; Urbani A
J Proteome Res; 2011 Feb; 10(2):416-28. PubMed ID: 21128686
[TBL] [Abstract][Full Text] [Related]
15. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
17. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.
Castagna A; Antonioli P; Astner H; Hamdan M; Righetti SC; Perego P; Zunino F; Righetti PG
Proteomics; 2004 Oct; 4(10):3246-67. PubMed ID: 15378690
[TBL] [Abstract][Full Text] [Related]
18. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
19. A proteomic study of potential VEGF-C-associated proteins in bladder cancer T24 cells.
Zhang HH; Qi F; Zu XB; Cao YH; Miao JG; Xu L; Qi L
Med Sci Monit; 2012 Nov; 18(11):BR441-9. PubMed ID: 23111735
[TBL] [Abstract][Full Text] [Related]
20. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
